IceCure Medical Ltd. announced it has received marketing authorization from the United States Food and Drug Administration (the FDA) for its next-generation single probe cryoablation system, the XSense? Cryoablation System with CryoProbes. XSense?

and its cryoprobes are cleared for all of the indications for which ProSense® has already received the requisite FDA clearance, including general minimally invasive cryoablation in the fields of general surgery, dermatology, neurology (including cryoanalgesia), thoracic surgery, ENT, gynecology, oncology, proctology and urology. The system is designed to destroy tissue by the application of extreme cold temperatures, including fibroadenomas, kidney tissue, liver metastases, tumors, skin lesions and warts. IceCure's platform technology, including the ProSense® Cryoablation System and XSense?

Cryoablation System and CryoProbes, provides a minimally invasive treatment option to destroy tumors by freezing them. The systems uniquely harness the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver. IceCure's cryoablation systems enhance patient and provider value by accelerating recovery, reducing pain, surgical risks and complications.

With easy, transportable design and liquid nitrogen utilization, ProSense® and XSense? open the door to fast and convenient office-based procedure for breast tumors.